Evidence map›Paper›PMID 29320652›Full record

ReviewThe New England journal of medicine2018

Multiple Sclerosis.

Daniel S Reich, Claudia F Lucchinetti, Peter A Calabresi

3 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The New England journal of medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 1,342 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,342citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05245344 unknown statusnot on this mapstarted 2022, after this paper: background citation

Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study

TypeobservationalSponsorNeuromed IRCCSRan2022 to 2023Enrolled154ConditionsRelapsing-Remitting Multiple Sclerosis (RRMS), Neuromyelitis Optica, HealthyArmsPeripheral blood withdrawal
NCT05451069 unknown statusnot on this mapstarted 2022, after this paper: background citation

Combined Neurofilament Light Chain ,Chitinase-3 Like-1 Protein Levels and Tolerogenic Plasmacytoid Dendritic Cells in Defining Disease Course in Multiple Sclerosis Patients

TypeobservationalSponsorAssiut UniversityRan2022 to 2025Enrolled42ConditionsMultiple SclerosisArmsNeurofilament Light Chain ,Chitinase-3 Like-1 Protein Levels and Tolerogenic plasmacytoid Dendritic Cells
NCT07788573 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

The Role of the FCRL5 Protein in the Pathophysiology of Multiple Sclerosis and Response to Treatment

TypeobservationalSponsorUniversité Catholique de LouvainRan2026 to 2029Enrolled90ConditionsMultiple SclerosisArmsA blood test every 6 months for MS patients., A single blood draw for the healthy volunteer, A single blood draw for the group of volunteers with Sjögren's syndrome
3 · Its place in the literature

Who cites it

1,342 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

1,282 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Daniel S ReichFrom the Translational Neuroradiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda (D.S.R.), and the Departments of Neurology and Neuroscience, Johns Hopkins School of Medicine, Baltimore (P.A.C.) - both in Maryland; and the Department of Neurology, Mayo Clinic, Rochester, MN (C.F.L.).
Claudia F LucchinettiFrom the Translational Neuroradiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda (D.S.R.), and the Departments of Neurology and Neuroscience, Johns Hopkins School of Medicine, Baltimore (P.A.C.) - both in Maryland; and the Department of Neurology, Mayo Clinic, Rochester, MN (C.F.L.).
Peter A CalabresiFrom the Translational Neuroradiology Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda (D.S.R.), and the Departments of Neurology and Neuroscience, Johns Hopkins School of Medicine, Baltimore (P.A.C.) - both in Maryland; and the Department of Neurology, Mayo Clinic, Rochester, MN (C.F.L.).

Funding

Multimodal MRI in Multiple SclerosisZIANS003119 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI REICH, DANIEL · 2010 to 2025
$53.4M
Imaging Neurodegeneration in Multiple SclerosisR01NS082347 · NINDS · JOHNS HOPKINS UNIVERSITY · PI PETER A CALABRESI, Shiv Saidha · 2013 to 2026
$7.0M
The Role of KV1.3 in Effector T cellsR01NS041435 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI CALABRESI, PETER A · 2000 to 2025
$5.8M
Mechanisms by which effector T cells modulate endogenous remyelinationR37NS041435 · NINDS · JOHNS HOPKINS UNIVERSITY · PI CALABRESI, PETER A · 2013 to 2019
$3.0M
Intramural NIH HHS ZIA NS003119NINDS NIH HHS R01 NS041435NINDS NIH HHS R01 NS082347NINDS NIH HHS R37 NS041435
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Multiple SclerosisAntibodies, MonoclonalBiomarkersBrainGlatiramer AcetateHumansImmunologic FactorsInterferon-betaMagnetic Resonance ImagingAntibodies, MonoclonalBiomarkersGlatiramer AcetateImmunologic FactorsInterferon-beta

Identifiers

PMID29320652
PMCPMC6942519

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.